DONATE
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-5 of 157 studies
-
Restore CFTR FunctionEnrolling
Phase 1/2 study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-801-01This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-801.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
30 days
-
-
Mucociliary ClearanceEnrolling
SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.
-
Age:
3 Years to 5 Years
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
54 weeks
-
-
Anti-InflammatoryEnrolling
Phase 2 study of LAU-7b in adults with CF (APPLAUD) , protocol number Laurent LAU-14-01This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the anti-inflammatory drug LAU-7b and will use a placebo control.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
6
-
Length of Participation:
189 days
-
-
Anti-InfectiveEnrolling
TEACH: Testing the effect of adding oral azithromycin to inhaled tobramycin in people with CF , protocol number TEACH-IP-15This phase 2 study is taking place at multiple care centers across the U.S. It will look at the effect of adding oral azithromycin to inhaled tobramycin and will use a placebo control.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25 to 100%
-
Number of Visits:
5
-
Length of Participation:
14 weeks
-
-
ObservationalEnrolling
PREDICT: NTM observational study , protocol number NTM-OB-17This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.
-
Age:
6 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
20
-
Length of Participation:
5 years
-
Showing 1-5 of 157 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Clinical Studies 101
-
Questions to Ask When Considering a Specific Trial
Learn moreClinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Learn moreNothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
How Do Clinical Trials Work
Learn moreEach clinical trial has a study sponsor and a protocol. Potential drugs must move through four well-defined phases of testing in patients.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More